)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
OraSure Technologies
OraSure Technologies (OSUR) investor relations material
OraSure Technologies Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary9 Nov, 2026
Executive summary
Q3 revenue rose 14% YoY to $30.9M as operational efficiencies supported higher margins and continued return-to-growth execution.
Strategy focuses on differentiated point-of-need diagnostics, portfolio expansion, localized capabilities and partnerships; 2027 revenue growth is expected to accelerate from 2026.
Financial highlights
Q3 revenue was $30.9M, up 14% YoY and 1% sequentially; 9M revenue rose 1% to $89.5M.
Q3 GAAP gross profit was $14.0M versus $11.8M; GAAP gross margin was 45.2% versus 43.5%, and non-GAAP gross margin was 45.9% versus 44.2%.
Q3 GAAP operating loss narrowed to $13.0M from $16.1M; non-GAAP operating loss was $10.2M versus $12.7M. G&A fell $2.4M to $12.0M.
Q3 GAAP net loss was $13.1M versus $13.7M; non-GAAP net loss was $10.1M versus $9.8M. GAAP diluted loss per share was $0.19, unchanged YoY.
9M net loss improved to $29.2M from $49.4M, including a $22.5M noncash contingent-consideration benefit.
Outlook and guidance
Q4 revenue guidance is $30M-$32M; FY 2026 guidance is $119.5M-$121.5M, implying 3.8%-5.6% growth and 4.7% at midpoint.
Q4 gross margin is expected to be similar to or slightly below Q3; operating expenses are expected to be similar to Q3 overall.
Cash flow from operations breakeven is now expected in H2 2027, later than the original plan to reach breakeven entering 2027.
2027 revenue growth is expected to accelerate versus 2026, with investment in topline growth, operating-model improvements and profitability.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from OraSure Technologies
- Q2 revenue $30.6M, margin 43.5%, net income $6.2M, FDA clearances, Q3 guidance $29.5–$32.5M.OSUR
Q2 2026 - Q1 2026 revenue was $27.9M, down 7% year-over-year, with margin gains and portfolio expansion.OSURQ1 2026
- Annual meeting covers director elections, compensation, stock plan, and board declassification.OSURProxy filing
- Proxy seeks votes on director elections, auditor, compensation, equity plan, and Board declassification.OSURProxy filing
- Board adds AI expertise, seeks declassification, and strengthens governance via Altai agreement.OSURProxy filing
- Cooperation with Altai Capital brings board changes and a proposal to declassify the Board.OSURProxy filing
- Growth strategy, governance, and capital allocation highlighted amid boardroom contest.OSURProxy filing
- Q2 revenue was $54.3M, with improved margins and new product momentum despite lower COVID-19 sales.OSURQ2 2024
- Q1 2025 revenue dropped 45% as COVID-19 sales fell, but Diagnostics grew 8%.OSURQ1 2025
Next OraSure Technologies earnings date
Q4 202624 Feb, 2027
OraSure Technologies
Next OraSure Technologies earnings date
Q4 202624 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
OraSure Technologies Inc. is a medical technology company that develops, manufactures, and markets diagnostic testing and sample collection devices. The company’s products include oral fluid diagnostic tests for infectious diseases, such as HIV and hepatitis, as well as molecular collection devices for genetic testing and drug screening. OraSure serves healthcare providers, laboratories, and consumers, offering solutions that enable easy and accurate testing and sample collection, often in non-invasive formats. The company is headquartered in Bethlehem, Pennsylvania, and its shares are listed on the NASDAQ.